Table 3 Molecular biology characteristic of RIG in the recent studies.
From: Clinical and molecular study of radiation-induced gliomas
Study | Type of study | Patient number | Methylation class | Copy number variations | Focal somatic alterations | Gene fusions |
|---|---|---|---|---|---|---|
DeSisto et al. (2021) | Multicentric | 32 | PedRTK1 (25/31) PXA (1/31) | 1p loss (10/25), 1q gain (13/25), 13q loss (10/25), 14q loss (10/25),PDGFRA gain/amplification (11/31), CDK4 amplification (6/31), CDKN2A loss (9/31), and BCOR loss (7/31) | PDGFRA, CDKN2A, BCOR, BRAF, NF1, TP53, CDK4 | MET fusions |
Deng et al. (2021) | Multicentric | 32 | PedRTK1 (29/32), PXA (3/32) | PDGFRA amplification (6/9 ALL-RIG; 11/23 MB- RIG), loss of CDKN2A/B (4/9 ALL-RIG; 17/23 MB-RIG) | TP53, CBL, PDGFRA, NTRK2, EGFR, RAF1, ATRX, BCOR | PTPRZ1::MET, CAPZA2::MET, FYCO1::RAF1, GFAP1::NTRK2 |
Whitehouse et. al (2021) | Metaanalysis | 102 | Not analyzed | PDGFRA amplification(10/21), CDK4 amplification(4/10), CDKN2A deletion(13/28), 1q gain(53%), 1p loss(47%), 13q loss(59%) | PDGFRA, TP53, ATRX, PTEN, PIK3CA, BRAF, IDH1 | GTF2I::BRAF |
Trkova et al. (this study) | Single-centre | 12 | PedRTK1 (9/10), PXA (1/10) | PDGFRA amplification (4/9), CDKN2A/B deletion(5/9), CDK4 amplification(1/9), MYCN amplification (1/9), 1p loss (6/9), 1q gain(1/9), 6q deletions (4/9) | BRAF, ROS1, PIK3CA, TP53, PTEN | not performed |
